VJHemOnc is committed to improving our service to you

ASH 2014 | MRD in myeloma and proteasome inhibition in amyloidosis

VJHemOnc is committed to improving our service to you

Rafael Fonseca

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter